Scleroderma, Systemic
Conditions
Brief summary
Systemic Sclerosis (SSc) is an auto-immune systemic disease characterized by vascular damage, cutaneous and visceral fibrosis and a dysimmune condition. Therapies in this disease remain insufficient and the complications resulting from organs involvement lead to strong morbi-mortality.The dermic infiltrate of the patients includes a strong proportion of Tcells. T cells and Natural Killer (NK) cells are potentially involved in the vascular damage of the SSc. However mechanisms at the onset of this endothelial cytotoxicity and its impact on the capacities of regeneration of the endothelial tissue remain poorly understood. Fractalkine is at the same time an endothelial membrane-bound adhesion molecule and a chemokine which is able to bind CX3CR1 expressed by the immune populations. The purpose of the project is to define the role displayed by cytotoxic, circulating immune populations of SSc patients in endothelial cytotoxicity as well as the role of the axis Fractalkine / CX3CR1 in mediating the interactions between the immune cytotoxic cells and the endothelium.
Interventions
OTHERblood samples
one blood sample will be done for dosage and role of Fractalkine in the serum. \- Functional study of the interactions between T cells and NK cells and / endothelial cells (HMVEC): immuno mediated endothelial cytotoxicity, endothelial activation and microparticles release by the HMVEC, endothelial progenitor cells analysis and evaluation of the endothelial lysis by fluorescence release.
Sponsors
Assistance Publique Hopitaux De Marseille
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* patients affected by SSc of more than 18 years * Healthy patients
Exclusion criteria
* Impossibility to take some blood * Current infection * Ongoing cancer * chemotherapy or a current radiotherapy * pregnant or breast-feeding women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| blood sample will be done for dosage of Fractalkine in the serum | 12 months |
Secondary
| Measure | Time frame |
|---|---|
| blood sample for functional study of the interactions between T cells and NK cells and / endothelial cells (HMVEC) | 12 months |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORBrigitte GRANEL, MD
Assistance Publique Hôpitaux de Marseille
Outcome results
None listed